Artículos de revistas
Diagnosis And Treatment Of Congenital Hemophilia With Inhibitors. A Latin American Perspective
Registro en:
Medicina. , v. 68, n. 3, p. 227 - 242, 2008.
257680
2-s2.0-47649085689
Autor
Bianco R.P.
Ozelo M.C.
Villaca P.R.
Solano M.H.
Cruz G.J.
Murillo C.M.
Chavez J.G.
Mendoza S.
Grecco I.R.
Ruiz-Saez A.
Institución
Resumen
The Committee of Latin America on the Therapeutics of Inhibitor Groups (CLOTTING) is composed of a number of hemophilia specialists from Latin America. The group aims to encourage the adoption of a good standard of care for Latin American patients with hemophilia. The occurrence of inhibitors in patients with hemophilia poses clinical challenges, and it is estimated that between 1 000 and 3 000 patients in Latin America are affected by hemophilia with inhibitors. There is an urgent need to establish a regional consensus and clinical guidelines for the diagnosis and treatment of these patients. We present an extensive review based on best current clinical practice and published literature, as seen from a Latin American perspective, taking into account the variable nature of hemophilia care available in the various countries in this Region. 68 3 227 242 Ehrenforth, S., Kreuz, W., Scharrer, I., Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs (1992) Lancet, 339, pp. 594-598 Katz, J., Prevalence of factor IX inhibitors among patients with haemophilia B: Results of a large-scale North American study (1996) Haemophilia, 2, pp. 28-31 Goudemand, J., Pharmaco-economic aspects of inhibitor treatment (1998) Eur J Haematol, 61, pp. 24-27 World Hemophilia Federation Report on Global Survey 2006. World Federation of Hemophilia, 2007. On www.wfh.org consulted on 23/04/2008Rieger, A., Roisenberg, I., Prevalence of factor VIII inhibitors in patients with hemophilia A in Brazil (1999) Thromb Haemost, 81, pp. 475-476 Fontes, E.M., Amorim, L., Carvalho, S.M., Farah, M.B., Hemophilia care in the state of Rio de Janeiro, Brazil (2003) Rev Panam Salud Pública, 13, pp. 124-128 Izquierdo-Ramírez, J., Contreras-Mulato, E.L., Sotelo-Ham, E.I., Incidence of inhibitors in children with hemophilia A (1988) Bol Med Hosp Infant Méx, 45, pp. 578-582 Boadas, A., Ruiz-Sáez, A., Arguello, A., de Bosch, N., Prevalence and acute bleeding treatment of allo and auto FVIII and FIX antibodies cases in Venezuela (2004) Haemophilia, 10, p. 56 Wight, J., Paisley, S., The epidemiology of inhibitors in hemophilia A: A systematic review (2003) Haemophilia, 9, pp. 418-435 Delivery of treatment for hemophilia (2002) Report of a joint WHO/WFH/ISTH meeting, , World Health Organization Hay, C.R., Brown, S., Collins, P.W., Keeling, D.M., Liesner, R., The diagnosis and management of factor VIII and IX inhibitors: A guideline from the United Kingdom Haemophilia Centre Doctors Organization (2006) Br J Haematol, 133, pp. 591-605 Ewing, N.P., Kasper, C.K., In vitro detection of mild inhibitors to factor VIII in hemophilia (1982) Am J Clin Pathol, 77, pp. 749-752 Verbruggen, B., Novakova, I., Wessels, H., Boezeman, J., van den Berg, M., Mauser-Bunschoten, E., The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: Improved specificity and reliability (1995) Thromb Haemost, 73, pp. 247-251 Giles, A.R., Verbruggen, B., Rivard, G.E., Teitel, J., Walker, I., A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the hemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis (1998) Thromb Haemost, 79, pp. 872-875 Verbruggen, B., van Heerde, W., Novakova, I., Lillicrap, D., Giles, A., A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen modification of the Bethesda factor VIII:C inhibitor assay (2002) Thromb Haemost, 88, pp. 362-364 White II, G.C., Rosendaal, F., Aledort, L.M., Lusher, J.M., Rothschild, C., Ingerslev, J., Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis (2001) Thromb Haemost, 85, p. 560 Kitchen, S., McCraw, A., (2000) Diagnosis of hemophilia and other bleeding disorders, , A laboratory manual. World Federation of Hemophilia http://www.med.unc.edu/isth, Available at:, Accessed November 2005http://www.wfh.org, Available at:, Accessed November 2005Oldenburg, J., Brackmann, H.H., Schwaab, R., Risk factors for inhibitor development in hemophilia A (2000) Haematologica, 85, pp. 7-13 Rossetti, L.C., Candela, M., Pérez Bianco, R., de Tezanos Pinto, M., Western, A., Goodeve, A., Analysis of factor VIII gene intron 1 inversion in Argentinean families with severe hemophilia A and a review of the literature (2004) Blood Coagul Fibrinolysis, 15, pp. 569-572 Santos, A., Montalva, O., Thomas, S., Veiga, M., De Paula, E., Ozelo, M., Genetic and ethnic aspects related to the development of inhibitors among Brazilian patients with hemophilia from five distinct geographical regions in Brazil (2006) Haemophilia, 12, pp. 1-154 Mantilla-Capacho, J.M., Beltrán-Miranda, C.P., Luna-Záizar, H., Frequency of intron 1 and 22 inversions of Factor VIII gene in Mexican patients with severe Hemophilia A (2007) Am J Hematol, 82, pp. 283-287 Guidelines for the management of hemophilia. World Federation of Hemophilia, 2005Girolami, A., Luzzatto, G., Varvarikis, C., Pellati, D., Sartori, R., Girolami, B., Main clinical manifestations of a bleeding diathesis: An often disregarded aspect of medical and surgical history taking (2005) Haemophilia, 11, pp. 193-202 Suggestions for the management of FVIII inhibitors (2000) Treatment of Hemophilia Monograph, , Inhibitor Subcommittee of the Association of Hemophilia Clinic Directors of Canada, revised edition, World Federation of Hemophilia Kasper, C., Diagnosis and management of inhibitors to factors VIII and IX (2004) Treatment of Hemophilia Monograph, , World Federation of Hemophilia Gringeri, A., Mannucci, P.M., Italian Association of Haemophilia Centres. Italian guidelines for the diagnosis and treatment of patients with hemophilia and inhibitors (2005) Haemophilia, 11, pp. 611-619 Key, N.S., Aledort, L.M., Beardsley, D., Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors (1998) Thromb Haemost, 80, pp. 912-918 Ingerslev, J., Sneppen, O., Hvid, I., Fredberg, U., Kristensen, H.L., Sindet-Petersen, S., Treatment of acute bleeding episodes with rFVIIa (1999) Vox Sang, 77, pp. 42-46 Santagostino, E., Gringeri, A., Mannucci, P.M., Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: The advantages of early intervention (1999) Br J Haematol, 104, pp. 22-26 Negrier, C., Goudemand, J., Sultan, Y., Bertrand, M., Rothschild, C., Lauroua, P., Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity (1997) Thromb Haemost, 77, pp. 1113-1119 Astermark, J., Donfield, S.M., DiMichelle, D.M., A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor - The Feiba® NovoSeven® Comparative Study (FENOC) (2007) Blood, 109, pp. 546-551 Young, G., Shafer, F.E., Rojas, P., Seremetis, S., Single 270 μg kg-1 dose rFVIIa vs. standard 90 μg kg-1 dose rFVIIa and APCC for home treatment of joint bleeds in hemophilia patients with inhibitors: A randomized comparison (2008) Haemophilia, 14, pp. 287-294 Ozelo, M.C., Villaça, P.R., De Almeida, J.O., A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with hemophilia and inhibitors in Brazil (2007) Haemophilia, 13, pp. 462-469 Kenet, G., Lubetsky, A., Luboshitz, J., Martinowitz, U., A new approach to treatment of bleeding episodes in young hemophilia patients: A single bolus megadose of recombinant activated factor VII (NovoSeven) (2003) J Thromb Haemost, 1, pp. 450-455 Parameswaran, R., Shapiro, A.D., Gill, J.C., Kessler, C.M., Dose effect and efficacy of rFVIIa in the treatment of hemophilia patients with inhibitors: Analysis from the Hemophilia and Thrombosis Research Society Registry (2005) Haemophilia, 11, pp. 100-106 Kavakli, K., Makris, M., Zulfikar, B., Erhardtsen, E., Abrams, Z.S., Kenet, G., Home treatment of haemarthroses using single dose regimen of recombinant activated factor VII in patients with hemophilia and inhibitors. A multi-centre, randomized, double blind, cross-over trial (2006) Thromb Haemost, 95, pp. 600-605 Santagostino, E., Mancuso, M.E., Rocino, A., Mancuso, G., Scaraggi, F., Mannucci, P.M., A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of haemarthroses in hemophiliacs with inhibitors (2006) J Thromb Haemost, 4, pp. 367-371 Schneiderman, J., Nugent, D.J., Young, G., Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe hemophilia and inhibitors (2004) Haemophilia, 10, pp. 347-351 Lusher, J.M., Shapiro, S.S., Palascak, J.E., Rao, A.V., Levine, P.H., Blatt, P.M., Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: A multicenter therapeutic trial (1980) NEJM, 303, pp. 421-425 Teitel, J., Berntorp, E., Collins, P., A systematic approach to controlling problem bleeds in patients with severe congenital hemophilia A and high-titre inhibitors (2007) Haemophilia, 13, pp. 256-263 Lloyd Jones, M., Wight, J., Paisley, S., Knight, C., Control of bleeding in patients with hemophilia A with inhibitors: A systematic review (2003) Haemophilia, 9, pp. 464-520 Ewenstein, B.M., Takemoto, C., Warrier, I., Nephrotic syndrome as a complication of immune tolerance in hemophilia B (1997) Blood, 89, pp. 1115-1116 Warrier, I., Lenk, H., Saidi, P., Pollmann, H., Tengborn, L., Berntorp, E., Nephrotic syndrome in hemophilia B patients with inhibitors (1998) Haemophilia, 4, p. 248 Warrier, I., Management of hemophilia B patients with inhibitors and anaphylaxis (1998) Haemophilia, 4, pp. 574-576 Strawczynski, H., Stachewitsch, A., Morgenstern, G., Shaw, M.E., Delivery of care to hemophilic children: Home care versus hospitalization (1973) Pediatrics, 51, pp. 986-991 Rabiner, S.F., Telfer, M.C., Fajardo, R., Home transfusions of hemophiliacs (1972) JAMA, 221, pp. 885-887 Levine, P., The home therapy program at the New England area hemophilia center (1977) Scand J Haematol, 31, pp. 37-51 Soucie, J.M., Symons, J.I., Evatt, B., Brettler, D., Huszti, H., Linden, J., Home-based factor infusion therapy and hospitalization for bleeding complications among males with hemophilia (2001) Haemophilia, 7, pp. 198-206 Solovieva, S., Clinical severity of disease, functional disability and health-related quality of life. Three-year follow-up study of 150 Finnish patients with coagulation disorders (2001) Haemophilia, 7, pp. 53-63 Teitel, J.M., Barnard, D., Israels, S., Lillicrap, D., Poon, M.C., Sek, J., Home management of hemophilia (2004) Haemophilia, 10, pp. 118-133 Ingerslev, J., Thykjær, H., Scheibel, E., Approaches towards successful home treatment in patients with inhibitors (1998) Eur J Haematol, 61, pp. 11-14 Young, G., McDaniel, M., Nugent, D.J., Prophylactic recombinant factor VIIa in hemophilia patients with inhibitors (2005) Haemophilia, 11, pp. 203-207 Saxon, B.R., Shanks, D., Jory, C.B., Williams, V., Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint (2001) Thromb Haemost, 86, pp. 1126-1127 Konkle, B.A., Ebbesen, L.S., Erhardtsen, E., Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors (2007) J Thromb Haemost, 5, pp. 1904-1913 Hoots, W.K., Ebbesen, L.S., Konkle, B.A., Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of hemophilia patients with inhibitors (2008) Haemophilia, 14, pp. 466-475 Leissinger, C.A., Prevention of bleeds in hemophilia patients with inhibitors: Emerging data and clinical direction (2004) Am J Hematol, 77, pp. 187-193 Luu, H., Ewenstein, B., FEIBA safety profile in multiple modes of clinical and home-therapy application (2004) Haemophilia, 10, pp. 10-16 Leissinger, C.A., Becton, D.L., Ewing, N.P., Valentino, L.A., Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with hemophilia A and inhibitors (2007) Haemophilia, 13, pp. 249-255 Villar, A., Aronis, S., Morfini, M., Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven®) in children vs. adults with hemophilia A (2004) Haemophilia, 10, pp. 352-359 Klitgaard, T., Nielsen, T.G., Overview of the human pharmacokinetics of recombinant activated factor VII (2008) Br J Clin Pharmacol, 65, pp. 3-11 Rodriguez-Merchan, E.C., Rocino, A., Ewenstein, B., Consensus perspectives on surgery in hemophilia patients with inhibitors: Summary statement (2004) Haemophilia, 10, pp. 50-52 Hilgartner, M.W., Factor replacement therapy (1989) Hemophilia in the Child and Adults, pp. 1-26. , Hilgartner MW, Pochedly C eds, New York, Raven Press Ltd (2000) Oxford Textbook of Surgery, , Morris PJ, Wood WG eds, 2nd edition. Oxford, Oxford University Press Rickard, K.A., Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in hemophilia (1995) Haemophilia, 1, pp. 8-13 Shapiro, A., Gilchrist, G.S., Hoots, W.K., Cooper, H.A., Gastineau, D.A., Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in hemophilia patients with inhibitors undergoing surgery (1998) Thromb Haemost, 80, pp. 773-778 Hvid, I., Rodriguez-Merchan, E.C., Orthopaedic surgery in haemophilic patients with inhibitors: An overview (2002) Haemophilia, 8, pp. 288-291 Rodriguez-Merchan, E.C., Rocino, A., Literature review of surgery management in inhibitor patients (2004) Haemophilia, 10, pp. 22-29 Abshire, T., Kenet, G., Recombinant factor VIIa: Review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors (2004) J Thromb Haemost, 2, pp. 899-909 Ingerslev, J., Efficacy and safety of Recombinant Factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors (2000) Semin Thromb Hemost, 26, pp. 425-432 Tjønnfjord, G.E., Brinch, L., Gedde-Dahl III, T., Brosstad, F.R., Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX (2004) Haemophilia, 10, pp. 174-178 Ingerslev, J., Sorensen, B., Role of recombinant activated factor VII as hemostatic support in orthopedic surgery (2006) TATM, 8, pp. 35-42 Obergfell, A., Auvinen, M.K., Mathew, P., Recombinant activated factor VII for haemophilia patients with inhibitors undergoing orthopaedic surgery: A review of the literature (2008) Haemophilia, 14, pp. 233-241 Ewenstein, B.M., Valentino, L.A., Journeycake, J.M., Consensus recommendations for use of central venous access devices in hemophilia (2004) Haemophilia, 10, pp. 629-648 Morado, M., Jimenez-Yuste, V., Villar, A., Complications of central venous catheters in patients with hemophilia and inhibitors (2001) Haemophilia, 7, pp. 551-556 Bollard, C.M., Teague, L.R., Berry, E.W., Ockelford, P.A., The use of central venous catheters (portacaths) in children with hemophilia (2000) Haemophilia, 6, pp. 66-70 O'Connell, N., Mc Mahon, C., Smith, J., Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with hemophilia and high responding inhibitors (2002) Br J Haematol, 116, pp. 632-635 Cooper, H.A., Jones, C.P., Campion, E., Roberts, H.R., Hedner, U., Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with hemophilia B during major orthopaedic procedures (2001) Haemophilia, 7, pp. 517-522 Colowick, A.B., Bohn, R.L., Avorn, J., Ewenstein, B.M., Immune tolerance induction in hemophilia patients with inhibitors: Costly can be cheaper (2000) Blood, 96, pp. 1698-1702 Brackmann, H.H., Gormsen, J., Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder (1977) Lancet, 2, p. 933 Key, N.S., Inhibitors in congenital coagulation disorders (2004) Br J Haematol, 127, pp. 379-391 Nilsson, I.M., Berntorp, E., Zettervall, O., Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII (1988) NEJM, 318, pp. 947-950 Mathias, M., Khair, K., Hann, I., Liesner, R., Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe hemophilia (2004) Br J Haematol, 125, pp. 366-368 Stasi, R., Brunetti, M., Stipa, E., Amadori, S., Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia (2004) Blood, 103, pp. 4424-4428 Carcao, M., Ungar, W.J., Feldman, B.M., Cost-utility analysis in evaluating prophylaxis in hemophilia (2004) Haemophilia, 10, pp. 50-57 Curtin, J., Misra, A., Teo, J., Webster, B., Lammi, A., Use of Rituximab as an alternative strategy for the management of difficult high titre inhibitors in children with hemophilia A (2004) Haemophilia, 10, p. 57 DiMichele, D., Immune tolerance therapy dose as an outcome predictor (2003) Haemophilia, 9, pp. 382-386 Mariani, G., Kroner, B., Immune tolerance in hemophilia with factor VIII inhibitors: Predictors of success (2001) Haematologica, 86, pp. 1186-1193 DiMichele, D., Inhibitors: Resolving diagnostic and therapeutic dilemmas (2002) Haemophilia, 8, pp. 280-287 Lenk, H., The German Registry of immune tolerance treatment in hemophilia-1999 update (2000) Haematologica, 85, pp. 45-47 Haya, S., Lopez, M.F., Aznar, J.A., Batlle, J., Immune tolerance treatment in hemophilia patients with inhibitors: The Spanish Registry (2001) Haemophilia, 7, pp. 154-159 DiMichele, D.M., Hoots, W.K., Pipe, S.W., Rivard, G.E., Santagostino, E., International workshop on immune tolerance induction: Consensus recomendations (2007) Haemophilia, 13, pp. 1-22 Kreuz, W., Mentzer, D., Auerswald, G., Becker, S., Joseph-Steiner, J., Successful immune tolerance therapy of FVIII inhibitor in children after changing from high to intermediate purity FVIII concentrate (1996) Haemophilia, 2, p. 19 Rocino, A., Papa, M.L., Salerno, E., Capasso, F., Miraglia, E., de Biasi, R., Immune tolerance induction in hemophilia A patients with high-responding inhibitors to factor VIII: Experience at a single institution (2001) Haemophilia, 7, pp. 33-38 DiMichele, D., Rivard, G., Hay, C., Antunes, S., Inhibitors in hemophilia: Clinical aspects (2004) Haemophilia, 10, pp. 140-145 Mauser-Bunschoten, E.P., Nieuwenhuis, H.K., Roosendaal, G., van den Berg, H.M., Low-dose immune tolerance induction in hemophilia A patients with inhibitors (1995) Blood, 86, pp. 983-988 Almeida, J., Paula, J.C., Toscano, R., Immune tolerance such as salvage therapy in severe hemophilia A patient with ultra high-responders inhibitors (2002) Haemophilia, 8, p. 538 Solano, M.H., Ramírez, C., Parra, L., Tratamiento de inhibidores del factor VIII en hemofilia. (1998) Acta Med Colomb, 23, p. 193 Carneiro, J.D.A., Bassit, R.P., Villaça, P.R., Sandoval, E.P.N., Silva, C.S.S.S., D'amico, E.A., Low-dose immune tolerance induction in hemophilia A children with inhibitors (2002) Haemophilia, 8, pp. 538-539 Wight, J., Paisley, S., Knight, C., Immune tolerance induction in patients with hemophilia A with inhibitors: A systematic review (2003) Haemophilia, 9, pp. 436-463 Tengborg, L., Hansson, S., Fasth, A., Lübeck, P.O., Berg, A., Ljung, R., Anaphylactoid reactions and nephrotic syndrome - a considerable risk during factor IX treatment in patients with hemophilia B and inhibitors: A report on the outcome in two brothers (1998) Haemophilia, 4, pp. 854-859 Schulman, S., Safety, efficacy and lessons from continuous infusion with rFVIIa (1998) Haemophilia, 4, pp. 564-567 Schulman, S., Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: Safety, monitoring, and cost effectiveness (2000) Semin Thromb Hemost, 26, pp. 421-424 Pruthi, R.K., Mathew, P., Valentino, L.A., Sumner, M.J., Seremetis, S., Hoots, W.K., Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in hemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial (2007) Thromb Haemost, 98, pp. 726-732 Smith, M.P., Ludlam, C.A., Collins, P.W., Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: Plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding (2001) Thromb Haemost, 86, pp. 949-953 Santagostino, E., Morfini, M., Rocino, A., Baudo, F., Scaraggi, F.A., Gringeri, A., Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors (2001) Thromb Haemost, 86, pp. 954-958 Mauser-Bunschoten, E.P., Koopman, M.M., Goede-Bolder, A.D., Efficacy of recombinant factor VIIa administered by continuous infusion to hemophilia patients with inhibitors (2002) Haemophilia, 8, pp. 649-656 Ludlam, C.A., Smith, M.P., Morfini, M., Gringeri, A., Santagostino, E., Savidge, G.F., A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: A pharmacokinetic and efficacy evaluation (2003) Br J Haematol, 120, pp. 808-813 Escobar, M.A., Recombinant Factor VIIa: The possibilities for monitoring (2003) TATM, 5, pp. 51-54 Young, G., Ebbesen, L.S., Viuff, D., Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in hemophilia A and B patients with inhibitors: A multicentre trial (2008) Blood Coagul Fibrinolysis, 19, pp. 276-282 Lak, M., Scharling, B., Blemings, A., Evaluation of rFVIIa (NovoSeven) in Glanzmann patients with thromboelastogram (2008) Haemophilia, 14, pp. 103-110 Sørensen, B., Ingerslev, J., Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa (2004) J Thromb Haemost, 2, pp. 102-110 Varadi, K., Turecek, F.L., Schwarz, H.P., Thrombin generation assay and other universal tests for monitoring hemophilia therapy (2004) Haemophilia, 10, pp. 17-21 Aledort, L.M., Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity (2004) J Thromb Haemost, 2, pp. 1700-1708 Sallah, S., Isaksen, M., Seremetis, S., Payne Rojkjaer, L., Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity: A rebuttal (2005) J Thromb Haemost, 3, pp. 820-822 Roberts, H.R., Monroe III, D.M., Hoffman, M., Safety profile of recombinant factor VIIa (2004) Semin Hematol, 41, pp. 101-108 Acute pain management: Operative or medical procedures and trauma (Agency of Health Care Policy and Research publications) (1992) Clinical Pharmacology, 11, pp. 391-414. , Agency of Health Care Policy and Research